Trial Outcomes & Findings for VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib (NCT NCT03400176)

NCT ID: NCT03400176

Last Updated: 2025-05-16

Results Overview

For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.

• Recruitment status: TERMINATED
• Study phase: PHASE1
• Target enrollment: 39 participants
• Primary outcome timeframe: Up to 7.8 months
• Results posted on: 2025-05-16

Participant Flow

A total of 39 patients were enrolled in the study. Fifteen patients participated in the dose escalation part across four treatment arms: VAY736 0.3 mg/kg Q2W + ibrutinib 420 mg, VAY736 1 mg/kg Q2W + ibrutinib 420 mg, VAY736 3 mg/kg Q2W + ibrutinib 420 mg, and VAY735 9 mg/kg + ibrutinib 420 mg. The remaining 24 subjects were enrolled in the expansion part and were treated with VAY736 3 mg/kg Q2W in combination with ibrutinib 420 mg or 280 mg.

The screening period began once patients had signed the study informed consent. Screening evaluations had to be completed within 21 days prior to the first dose of study treatment with the exception of baseline tumor assessments that could be conducted within 28 days prior to the first dose of study treatment. After screening, the treatment period started on Cycle 1 Day 1.

Participant milestones

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 280mg VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 280 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Dose Escalation STARTED	4	3	0	4	4
Dose Escalation COMPLETED	3	2	0	4	2
Dose Escalation NOT COMPLETED	1	1	0	0	2
Dose Expansion STARTED	0	0	1	23	0
Dose Expansion Group A	0	0	0	19	0
Dose Expansion Group B	0	0	1	4	0
Dose Expansion COMPLETED	0	0	0	19	0
Dose Expansion NOT COMPLETED	0	0	1	4	0

Reasons for withdrawal

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 280mg VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 280 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Dose Escalation Progressive disease	1	1	0	0	1
Dose Escalation Patient decision	0	0	0	0	1
Dose Expansion Patient decision	0	0	0	1	0
Dose Expansion Adverse Event	0	0	0	1	0
Dose Expansion Physician Decision	0	0	0	1	0
Dose Expansion Progressive disease	0	0	1	1	0

Baseline Characteristics

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Baseline characteristics by cohort

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 280mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 280 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	Total n=39 Participants Total of all reporting groups
Age, Continuous	69.3 years STANDARD_DEVIATION 6.02 • n=5 Participants	61.0 years STANDARD_DEVIATION 1.73 • n=7 Participants	57.0 years n=5 Participants	63.5 years STANDARD_DEVIATION 10.36 • n=4 Participants	65.0 years STANDARD_DEVIATION 10.42 • n=21 Participants	63.9 years STANDARD_DEVIATION 9.50 • n=8 Participants
Age, Customized 18 - < 65 years	1 Participants n=5 Participants	3 Participants n=7 Participants	1 Participants n=5 Participants	12 Participants n=4 Participants	2 Participants n=21 Participants	19 Participants n=8 Participants
Age, Customized 65 - < 85 years	3 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	15 Participants n=4 Participants	2 Participants n=21 Participants	20 Participants n=8 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	7 Participants n=4 Participants	3 Participants n=21 Participants	11 Participants n=8 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	20 Participants n=4 Participants	1 Participants n=21 Participants	28 Participants n=8 Participants
Race/Ethnicity, Customized White	4 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	26 Participants n=4 Participants	3 Participants n=21 Participants	36 Participants n=8 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=8 Participants
Race/Ethnicity, Customized Missing	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants

PRIMARY outcome

Timeframe: 28 days

Population: All patients in the dose escalation part who received at least one dose of study treatment and who either met the minimum exposure criterion defined in the protocol and had sufficient safety evaluations, or experienced a DLT during the first 28 days of treatment.

A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of treatment with the combination of VAY736 and ibrutinib and meets the criteria defined in the study protocol. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 (Escalation Only)	0 Participants	0 Participants	0 Participants	0 Participants	—

PRIMARY outcome

Timeframe: From first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months

Population: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

Number of participants with AEs (any AE regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.

AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE.

All patients were followed for a 30-day safety follow-up period subsequent to completion of VAY736 therapy. No new AEs or SAEs were collected beyond the 30-day safety follow-up or during the efficacy follow up period.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) AEs	4 Participants	3 Participants	1 Participants	27 Participants	4 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Treatment-related AEs	2 Participants	2 Participants	1 Participants	15 Participants	1 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) AEs with grade >=3	1 Participants	2 Participants	1 Participants	12 Participants	0 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Treatment-related AEs with grade >=3	0 Participants	1 Participants	1 Participants	7 Participants	0 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) SAEs	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Treatment-related SAEs	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Fatal SAEs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to 7.8 months

Population: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Number of Participants With Dose Reductions and Dose Interruptions of VAY736 At least one dose reduction or interruption	0 Participants	1 Participants	0 Participants	5 Participants	0 Participants
Number of Participants With Dose Reductions and Dose Interruptions of VAY736 At least one dose reduction	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Dose Reductions and Dose Interruptions of VAY736 At least one dose interruption	0 Participants	1 Participants	0 Participants	5 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to 8.5 months

Population: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Number of Participants With Dose Reductions and Dose Interruptions of Ibrutinib At least one dose reduction	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Dose Reductions and Dose Interruptions of Ibrutinib At least one dose reduction or interruption	0 Participants	1 Participants	0 Participants	10 Participants	0 Participants
Number of Participants With Dose Reductions and Dose Interruptions of Ibrutinib At least one dose interruption	0 Participants	1 Participants	0 Participants	10 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to 7.8 months

Population: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

Dose intensity of VAY736 was calculated as: Actual Cumulative dose (mg/kg) / (Duration of exposure in weeks/2)

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Dose Intensity of VAY736	0.30 mg/kg/2 weeks Interval 0.3 to 0.3	0.98 mg/kg/2 weeks Interval 0.9 to 1.0	3.00 mg/kg/2 weeks Interval 3.0 to 3.0	3.00 mg/kg/2 weeks Interval 1.4 to 3.0	8.97 mg/kg/2 weeks Interval 8.9 to 9.0

PRIMARY outcome

Timeframe: Up to 8.5 months

Population: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

Dose intensity of ibrutinib was calculated as: Actual Cumulative dose (mg) / (Duration of exposure in days)

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Dose Intensity of Ibrutinib	420.00 mg/day Interval 420.0 to 420.0	420.00 mg/day Interval 407.7 to 420.0	280.00 mg/day Interval 280.0 to 280.0	420.00 mg/day Interval 395.7 to 420.0	420.00 mg/day Interval 420.0 to 420.0

SECONDARY outcome

Timeframe: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.

Population: All patients who received at least one dose of study treatment in the dose expansion part of the study.

Percentage of participants with Complete Response (CR) or Complete Response with Incomplete Marrow Recovery (CRi) by investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=19 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=24 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
CR or CRi Rate at C9 for Expansion Arm A and Arm B by Investigator Per IWCLL	47.4 percentage of participants Interval 27.4 to 68.0	0 percentage of participants Interval 0.0 to 95.0	0 percentage of participants Interval 0.0 to 52.7	37.5 percentage of participants Interval 21.2 to 56.3	—

SECONDARY outcome

Timeframe: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.

Population: All patients who received at least one dose of study treatment in the dose expansion part of the study.

The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach.

A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%.

Values estimated from the model at Cycle 9 are presented in the table. Posterior geometric mean for CR/CRi rate and 90% credible intervals in each group are presented.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=19 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=24 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Posterior Mean of CR or CRi Response Rate at C9 for Expansion Arm A and Arm B (Bayesian Analysis)	45.68 percentage of participants Interval 28.1 to 63.7	11.11 percentage of participants Interval 0.0 to 51.6	4.76 percentage of participants Interval 0.0 to 23.0	36.63 percentage of participants Interval 21.8 to 52.7	—

SECONDARY outcome

Timeframe: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.

Population: All patients who received at least one dose of study treatment in the dose expansion part of the study.

The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach.

A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%.

Values estimated from the model at Cycle 9 are presented in the table. The posterior probability that the true CR/CRi rate falls in the activity intervals defined below is presented:

• [0, 20%) - clinically not meaningful
• [20%, 40%) - moderate clinical benefit
• [40%, 100%] - superior clinical benefit

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=19 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=24 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Posterior Probability That the True CR or CRi Response Rate at C9 for Expansion Arm A and Arm B Falls in Pre-defined Activity Intervals (Bayesian Analysis) [0, 20%) - clinically not meaningful	0.5 percentage of participants	80.2 percentage of participants	93.6 percentage of participants	3 percentage of participants	—
Posterior Probability That the True CR or CRi Response Rate at C9 for Expansion Arm A and Arm B Falls in Pre-defined Activity Intervals (Bayesian Analysis) [20%, 40%) - moderate clinical benefit	30.4 percentage of participants	11.3 percentage of participants	5.3 percentage of participants	61.8 percentage of participants	—
Posterior Probability That the True CR or CRi Response Rate at C9 for Expansion Arm A and Arm B Falls in Pre-defined Activity Intervals (Bayesian Analysis) 40%, 100%] - superior clinical benefit	69.1 percentage of participants	8.5 percentage of participants	1.1 percentage of participants	35.2 percentage of participants	—

SECONDARY outcome

Timeframe: Up to approximately 2.5 years

Population: All patients who received at least one dose of study treatment in the dose escalation part of the study.

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.

ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=15 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Escalation Part	50.0 percentage of participants Interval 9.8 to 90.2	0 percentage of participants Interval 0.0 to 63.2	50.0 percentage of participants Interval 9.8 to 90.2	50.0 percentage of participants Interval 9.8 to 90.2	40.0 percentage of participants Interval 19.1 to 64.0

SECONDARY outcome

Timeframe: Up to approximately 2.7 years

Population: All patients who received at least one dose of study treatment in the dose expansion part of the study.

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.

ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=19 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=24 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Expansion Part	84.2 percentage of participants Interval 64.1 to 95.6	0 percentage of participants Interval 0.0 to 95.0	25.0 percentage of participants Interval 1.3 to 75.1	70.8 percentage of participants Interval 52.1 to 85.4	—

SECONDARY outcome

Timeframe: Up to approximately 2.5 years

Population: All patients who received at least one dose of study treatment in the dose escalation part of the study.

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.

TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer.

If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment.

TTP was analyzed using Kaplan-Meier estimates.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=15 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Time to Progression (TTP) in the Dose Escalation Part	23.3 months Interval 2.8 to Not estimable due to insufficient number of participants with events.	8.3 months Interval 1.8 to Not estimable due to insufficient number of participants with events.	24.2 months Interval 5.6 to Not estimable due to insufficient number of participants with events.	19.4 months Interval 2.8 to Not estimable due to insufficient number of participants with events.	19.4 months Interval 2.8 to 25.1

SECONDARY outcome

Timeframe: Up to approximately 2.7 years

Population: All patients who received at least one dose of study treatment in the dose expansion part of the study.

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.

TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer.

If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment.

TTP was analyzed using Kaplan-Meier estimates.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=19 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=24 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Time to Progression (TTP) in the Dose Expansion Part	NA months Interval 26.3 to Not estimable due to insufficient number of participants with events.	2.3 months Not estimable due to insufficient number of participants with events.	NA months Not estimable due to insufficient number of participants with events.	NA months Interval 26.3 to Not estimable due to insufficient number of participants with events.	—

SECONDARY outcome

Timeframe: Up to Cycle 9 Day 1. The duration of each cycle was 28 days.

Population: All patients in the dose expansion arm B who received at least one dose of study treatment.

Clearance was defined as less than 1% mutation bearing alleles (BTKC481 and/or PLCγ2) during treatment.

Negative mutation is defined as having clearance of the baseline ibrutinib resistance mutation during treatment (up to Cycle 9 (C9)).

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=5 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Percentage of Participants With Clearance of Ibrutinib Resistance Mutation During Treatment (up to C9) for Expansion Arm B	0 percentage of participants Interval 0.0 to 95.0	0 percentage of participants Interval 0.0 to 52.7	0 percentage of participants Interval 0.0 to 45.1	—	—

SECONDARY outcome

Timeframe: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one primary PK parameter and did not vomit within 8 hours after the dosing of ibrutinib. Patients were analyzed according to the study treatment received.

Pharmacokinetic (PK) parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Maximum Observed Serum Concentration (Cmax) of VAY736 Cycle 1	9.61 µg/mL Geometric Coefficient of Variation 23.0	15.8 µg/mL Geometric Coefficient of Variation 59.8	65.9 µg/mL	59.4 µg/mL Geometric Coefficient of Variation 15.8	178 µg/mL Geometric Coefficient of Variation 26.7
Maximum Observed Serum Concentration (Cmax) of VAY736 Cycle 3	11.2 µg/mL Geometric Coefficient of Variation 21.2	21.6 µg/mL Geometric Coefficient of Variation 38.8	—	72.5 µg/mL Geometric Coefficient of Variation 33.9	260 µg/mL Geometric Coefficient of Variation 13.3

SECONDARY outcome

Timeframe: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one primary PK parameter and did not vomit within 8 hours after the dosing of ibrutinib. Patients were analyzed according to the study treatment received.

PK parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Time to Reach Maximum Serum Concentration (Tmax) of VAY736 Cycle 1	4.30 hours Interval 2.4 to 6.0	3.90 hours Interval 2.0 to 5.8	2.20 hours Interval 2.2 to 2.2	4.70 hours Interval 2.0 to 6.1	5.80 hours Interval 2.2 to 6.0
Time to Reach Maximum Serum Concentration (Tmax) of VAY736 Cycle 3	2.00 hours Interval 2.0 to 2.1	2.20 hours Interval 2.1 to 2.3	—	2.10 hours Interval 2.0 to 22.7	2.15 hours Interval 0.0 to 2.7

SECONDARY outcome

Timeframe: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one primary PK parameter and did not vomit within 8 hours after the dosing of ibrutinib. Patients were analyzed according to the study treatment received.

PK parameters were calculated based on VAY7736 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of VAY736 Cycle 1	46.0 hr*µg/mL Geometric Coefficient of Variation 29.1	55.5 hr*µg/mL Geometric Coefficient of Variation 46.0	217 hr*µg/mL	256 hr*µg/mL Geometric Coefficient of Variation 19.1	930 hr*µg/mL Geometric Coefficient of Variation 25.0
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of VAY736 Cycle 3	75.6 hr*µg/mL Geometric Coefficient of Variation 31.7	166 hr*µg/mL Geometric Coefficient of Variation 48.2	—	368 hr*µg/mL Geometric Coefficient of Variation 55.2	1780 hr*µg/mL Geometric Coefficient of Variation 18.1

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one primary PK parameter and did not vomit within 8 hours after the dosing of ibrutinib. Patients were analyzed according to the study treatment received.

PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib Cycle 1 Day 1	93.5 ng/mL Geometric Coefficient of Variation 120.6	123 ng/mL Geometric Coefficient of Variation 28.8	212 ng/mL	83.3 ng/mL Geometric Coefficient of Variation 146.9	104 ng/mL Geometric Coefficient of Variation 62.7
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib Cycle 1 Day 8	94.9 ng/mL Geometric Coefficient of Variation 84.4	158 ng/mL Geometric Coefficient of Variation 53.0	—	62.2 ng/mL Geometric Coefficient of Variation 149.4	97.0 ng/mL Geometric Coefficient of Variation 54.1

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one primary PK parameter and did not vomit within 8 hours after the dosing of ibrutinib. Patients were analyzed according to the study treatment received.

PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Time to Reach Maximum Plasma Concentration (Tmax) of Ibrutinib Cycle 1 Day 1	2.10 hours Interval 1.9 to 2.1	2.00 hours Interval 2.0 to 2.1	2.30 hours Interval 2.3 to 2.3	2.10 hours Interval 0.6 to 6.8	2.00 hours Interval 1.9 to 2.2
Time to Reach Maximum Plasma Concentration (Tmax) of Ibrutinib Cycle 1 Day 8	2.00 hours Interval 1.5 to 6.0	2.00 hours Interval 1.9 to 2.1	—	2.00 hours Interval 0.5 to 2.5	2.00 hours Interval 1.9 to 2.0

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one primary PK parameter and did not vomit within 8 hours after the dosing of ibrutinib. Patients were analyzed according to the study treatment received.

PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Ibrutinib Cycle 1 Day 1	541 hr*ng/mL Geometric Coefficient of Variation 145.3	938 hr*ng/mL Geometric Coefficient of Variation 63.4	890 hr*ng/mL	696 hr*ng/mL Geometric Coefficient of Variation 98.5	634 hr*ng/mL Geometric Coefficient of Variation 34.6
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Ibrutinib Cycle 1 Day 8	338 hr*ng/mL Geometric Coefficient of Variation 69.6	552 hr*ng/mL Geometric Coefficient of Variation 41.8	—	226 hr*ng/mL Geometric Coefficient of Variation 134.0	323 hr*ng/mL Geometric Coefficient of Variation 54.7

SECONDARY outcome

Timeframe: Baseline (before first dose) and post-baseline (assessed throughout the VAY736 treatment, up to 7.8 months).

Population: Patients who received at least 1 dose of VAY736 and had a determinant baseline immunogenicity (IG) sample and at least 1 determinant post-baseline IG sample for assessing anti-VAY736 antibodies. Patients were analyzed according to the study treatment received.

VAY736 immunogenicity was evaluated in serum samples. Anti-drug antibodies (ADA) status was defined as follows:

• ADA-negative at baseline: baseline sample where assay is ADA negative
• ADA-positive at baseline: baseline sample where assay is ADA positive
• ADA-negative post-baseline: ADA-negative sample at baseline and at least 1 post-baseline sample, all of which are ADA-negative samples
• Treatment-induced ADA-positive: ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample
• Treatment-boosted ADA-positive: ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample
• ADA-inconclusive post-baseline: patient who does not qualify for any of the above definitions

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
Number of Participants With Anti-VAY736 Antibodies ADA-positive at baseline	0 participants	0 participants	0 participants	3 participants	0 participants
Number of Participants With Anti-VAY736 Antibodies ADA-negative at baseline	4 participants	3 participants	1 participants	24 participants	4 participants
Number of Participants With Anti-VAY736 Antibodies ADA-negative post-baseline	4 participants	3 participants	1 participants	24 participants	4 participants
Number of Participants With Anti-VAY736 Antibodies ADA-inconclusive post-baseline	0 participants	0 participants	0 participants	0 participants	0 participants
Number of Participants With Anti-VAY736 Antibodies Treatment-induced ADA-positive	0 participants	0 participants	0 participants	0 participants	0 participants
Number of Participants With Anti-VAY736 Antibodies Treatment-boosted ADA-positive	0 participants	0 participants	0 participants	0 participants	0 participants

POST_HOC outcome

Timeframe: On-treatment deaths: up to approximately 8.8 months. Post-treatment deaths: up to approximately 2.7 years

Population: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

On-treatment deaths were collected from first dose of study treatment to 30 days after the last dose of VAY736. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study. All deaths refer to the sum of on-treatment and post-treatment deaths.

Outcome measures

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 0.3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 Participants VAY736 1 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=1 Participants VAY736 3 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=27 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 Participants VAY736 9 mg/kg i.v. once every 2 weeks in combination with ibrutinib 420 mg oral once daily
All-Collected Deaths On-treatment deaths	0 participants	0 participants	0 participants	0 participants	0 participants
All-Collected Deaths Post-treatment deaths	0 participants	0 participants	0 participants	1 participants	0 participants
All-Collected Deaths All deaths	0 participants	0 participants	0 participants	1 participants	0 participants

Adverse Events

VAY736 0.3mg/kg Q2W + Ibrutinib 420mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

VAY736 1mg/kg Q2W + Ibrutinib 420mg

Serious events: 2 serious events

Other events: 3 other events

Deaths: 0 deaths

VAY736 3mg/kg Q2W + Ibrutinib 280mg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

VAY736 3mg/kg Q2W + Ibrutinib 420mg

Serious events: 2 serious events

Other events: 27 other events

Deaths: 0 deaths

VAY736 9mg/kg Q2W + Ibrutinib 420mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

All patients_On-treatment

Serious events: 4 serious events

Other events: 39 other events

Deaths: 0 deaths

VAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatment

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

VAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatment

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

VAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatment

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

VAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatment

Serious events: 0 serious events

Other events: 0 other events

Deaths: 1 deaths

VAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 3mg/kg Q2W + Ibrutinib 280mg n=1 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=27 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 participants at risk Safety data up to 30 days after the last dose of VAY736	All patients_On-treatment n=39 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Non-cardiac chest pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Escherichia sepsis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Neutrophil count decreased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

Other adverse events

Measure	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg n=4 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 1mg/kg Q2W + Ibrutinib 420mg n=3 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 3mg/kg Q2W + Ibrutinib 280mg n=1 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 3mg/kg Q2W + Ibrutinib 420mg n=27 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 9mg/kg Q2W + Ibrutinib 420mg n=4 participants at risk Safety data up to 30 days after the last dose of VAY736	All patients_On-treatment n=39 participants at risk Safety data up to 30 days after the last dose of VAY736	VAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.	VAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment Deaths collected in the post-treatment period (starting from Day 31 after last dose of VAY736). No AEs were collected during this period.
Blood and lymphatic system disorders Anaemia	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	100.0% 3/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	29.6% 8/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	35.9% 14/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Blood and lymphatic system disorders Lymph node pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Blood and lymphatic system disorders Neutropenia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	100.0% 1/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Cardiac disorders Atrial fibrillation	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Cardiac disorders Palpitations	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Cardiac disorders Sinus bradycardia	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Cardiac disorders Sinus tachycardia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	10.3% 4/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Eye disorders Cataract	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Eye disorders Retinal tear	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Eye disorders Vision blurred	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Eye disorders Vitreous floaters	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Abdominal distension	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Abdominal pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Constipation	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	11.1% 3/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	10.3% 4/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Diarrhoea	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	100.0% 3/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	17.9% 7/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Dyspepsia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	11.1% 3/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	10.3% 4/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Frequent bowel movements	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Nausea	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	15.4% 6/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Oral pain	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Stomatitis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Gastrointestinal disorders Vomiting	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	10.3% 4/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Chills	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Fatigue	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.9% 7/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	20.5% 8/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Influenza like illness	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Malaise	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Non-cardiac chest pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Oedema peripheral	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
General disorders Pyrexia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Bronchitis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Conjunctivitis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Cystitis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Hordeolum	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Onychomycosis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Paronychia	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Sinusitis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Upper respiratory tract infection	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Infections and infestations Urinary tract infection	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Injury, poisoning and procedural complications Contusion	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Injury, poisoning and procedural complications Fall	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	11.1% 3/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Injury, poisoning and procedural complications Skin abrasion	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Injury, poisoning and procedural complications Vaccination complication	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Alanine aminotransferase increased	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	11.1% 3/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Amylase increased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Aspartate aminotransferase increased	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	11.1% 3/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Blood alkaline phosphatase increased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Blood bilirubin increased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	10.3% 4/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Blood creatinine increased	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	15.4% 6/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Blood iron decreased	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Blood lactate dehydrogenase increased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	11.1% 3/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations International normalised ratio increased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Lipase increased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	22.2% 6/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	15.4% 6/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Lymphocyte count decreased	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	22.2% 6/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	20.5% 8/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Lymphocyte count increased	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Neutrophil count decreased	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	100.0% 3/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	23.1% 9/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Platelet count decreased	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations Weight increased	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Investigations White blood cell count decreased	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hyperglycaemia	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	100.0% 3/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	37.0% 10/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	41.0% 16/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypermagnesaemia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypernatraemia	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypertriglyceridaemia	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.9% 7/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	30.8% 12/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hyperuricaemia	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.9% 7/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	23.1% 9/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypoglycaemia	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypokalaemia	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	22.2% 6/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	17.9% 7/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Arthralgia	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	15.4% 6/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	14.8% 4/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	12.8% 5/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Flank pain	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Joint swelling	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Muscle spasms	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	50.0% 2/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Osteoporosis postmenopausal	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	18.5% 5/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	15.4% 6/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Musculoskeletal and connective tissue disorders Tenosynovitis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Nervous system disorders Dizziness	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Nervous system disorders Headache	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	11.1% 3/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	17.9% 7/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Nervous system disorders Paraesthesia	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Psychiatric disorders Agitation	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Psychiatric disorders Insomnia	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Renal and urinary disorders Haematuria	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Renal and urinary disorders Nephrolithiasis	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Renal and urinary disorders Renal colic	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Renal and urinary disorders Urinary incontinence	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Renal and urinary disorders Urinary retention	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Reproductive system and breast disorders Pelvic pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Respiratory, thoracic and mediastinal disorders Cough	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	15.4% 6/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Respiratory, thoracic and mediastinal disorders Nasal congestion	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.7% 3/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Respiratory, thoracic and mediastinal disorders Sinus pain	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Skin and subcutaneous tissue disorders Dermatitis allergic	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Skin and subcutaneous tissue disorders Dermatitis bullous	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	7.4% 2/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Skin and subcutaneous tissue disorders Pruritus	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	3.7% 1/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	5.1% 2/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	33.3% 1/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Skin and subcutaneous tissue disorders Skin lesion	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	2.6% 1/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
Vascular disorders Hypertension	25.0% 1/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	66.7% 2/3 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/1 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	22.2% 6/27 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	0.00% 0/4 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	23.1% 9/39 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.	— 0/0 • Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years. Deaths in the post-treatment period are not considered Adverse Events (AEs). No AEs were collected in the post-treatment period. Safety was analyzed in the Safety set including all patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

Additional Information

Study Director

Novartis Pharmaceuticals

Phone: 862-778-8300

Email: Novartis.email@novartis.com

Results disclosure agreements

• Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
• Publication restrictions are in place

Restriction type: OTHER